Phosphatases of regenerating liver: A novel target in human solid tumors

Chinese Medical Journal

Volumn 121, Issue 15, 2008, Pages 1469-1474

  Zhao, Wen Bo ^a   Wang, Xin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Invasion; Metastasis; Phosphatases of regenerating liver; Tumor

Indexed keywords

BENZYLIDENE RHODANINE DERIVATIVE; BIFLAVONOID; GINKGETIN; PENTAMIDINE; PHOSPHATASE; PHOSPHATASE OF REGENERATING LIVER; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 4A1; PROTEIN TYROSINE PHOSPHATASE 4A2; PROTEIN TYROSINE PHOSPHATASE 4A3; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; SCIADOPITYSIN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INVASION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMOSOME 1P; CHROMOSOME 6Q; CHROMOSOME 8Q; DIAGNOSTIC VALUE; HUMAN; LIVER CARCINOMA; LYMPH NODE METASTASIS; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 51349115110     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200808010-00024     Document Type: Article

References (49)

1. Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacol Ther 2002; 93: 307-317.
2. Burridge K, Sastry SK, Sallee JL. Regulation of cell adhesion by protein-tyrosine phosphatases in cell-matrix adhesion. J Biol Chem 2006; 281: 15593-15596.
3. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 117: 699-711.
4. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Bio 2006; 7: 833-846.
5. Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005; 4: 1653-1661.
6. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 1994; 14: 3752-3762.
7. Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 1998; 244: 421-427.
8. Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004; 343: 417-433.
9. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000; 275: 21444-21452.
10. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, et al. Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 2001; 283: 1061-1068.
11. Dumaual CM, Sandusky GE, Crowell PL, Randall SK. Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. J Histochem Cytochem 2006; 54: 1401-1412.
12. Wang J, Kirby CE, Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal Mitosis. J Biol Chem 2002; 277: 46659-46668.
13. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-2896.
14. Wang Q, Holmes DIR, Powell SM, Lu QL, Waxman J. Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene. Cancer Lett 2001; 175: 63-69.
15. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, Croix BS, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001; 294: 1343-1346.
16. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 2004; 164: 2039-2054.
17. Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 2004; 71: 176-184.
18. Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J, et al. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun 2006; 348: 229-237.
19. Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 2006; 17: 1517-1522.
20. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 2005; 11: 6835-6839.
21. Diamond RH, Peters C. Jung SP. Greenbaum LE, Haber BA. Silberg DG, et al. Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine. Am J Physiol-Gastr L 1996; 271: G121-G129.
22. Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL. Enhanced cell cycle progression and down regulation of p21Cip1/Waf1 by PRL tyrosine phosphatases. Cancer Lett 2003; 202: 201-211.
23. Cates C, Michael R. Stayrook K, Harvey K. Burke Y. Randall S et al. Prenylation of oncogene human PTP (CAAX) protein tyrosine phosphatases. Cancer Lett 1996, 110: 49-55.
24. Sun JP, Luo Y, Yu X, Wang WQ, Zhou B, Liang F, et al. Phosphatase activity, trimerization, and the C-terminal polyhasic region are all required for PRL1-mediated cell growth and migration. J Biol Chem 2007; 282: 29043-29051.
25. Obaya AJ. Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002; 59: 126-142.
26. Bardelli A, Saha S. Sager JA, Romans KE, Xin B, Markowitz SD, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res 2003; 9: 5607-5615.
27. Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate Rho family GTPases to promote invasion and motility. Cancer Res 2006; 66: 3153-3161.
28. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 2004; 10: 7318-7328.
29. Achiwa H, Lazo JS. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res 2007; 67: 643-650.
30. Miskad U, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 2007; 450: 303-310.
31. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL-3 promotes cell invasion and proliferation by down-regulation of csk leading to Src activation. J Biol Chem 2007; 282: 5413-5419.
32. Kong L, Li Q, Wang L, Liu Z, Sun T. The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas. Neuropathology 2007; 27: 516-521.
33. Qian F, Li YP, Sheng X, Zhang ZC, Song R, Dong W, et al. PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med 2007; 13: 151-159.
34. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
35. Cuo K, Li J, Tang JP, Koh V, Gan BQ, Zeng Q. Catalytic domain of PRL-3 plays an essential role in tumor metastasis, formation of PRL-3 tumors inside the blood vessel. Cancer Biol Ther 2004; 3: 945-951.
36. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64: 7857-7866.
37. Rouleau C, Roy A, St. Martin T, Dufault MR, Boutin P, Liu D, et al. Protein tyrosinc phosphatase PRL-3 in malignant cells and endothelial cells: expression and function, Mol Cancer Ther 2006; 5: 219-229.
38. Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, et al. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res 2006; 66: 9625-9635.
39. Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Identification of integrin a1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun 2006; 342: 179-183.
40. Peng Y, Du K, Ramirez S, Diamond RH, Taub R. Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. J Biol Chem 1999; 274: 4513-4520.
41. Peters CS, Liang X, Li S, Kannan S, Peng Y, Taub R, et al. ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. J Biol Chem 2001, 276: 13718-13726.
42. Daoud SS, Munson PJ, Reinhold W, Voung L, Prabhu VV, Yu Q, et al. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003; 63: 2782-2793.
43. Fonternaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277: 43359-43368.
44. Kyng KJ, May A, Brosh RM, Cheng WH, Chen C, Becker KG, et al. The transcriptional response after oxidative stress is defective in Cockayne syndrome group B cells. Oncogene 2003; 22: 1135-1149.
45. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 2002; 1: 1255-1264.
46. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, et al. Pentamidine reduces hERG expression to prolong the QT interval. Brit J Pharmacol 2005; 145: 15-23.
47. Choi SK, Oh HM, Lee SK, Jeong DG, Ryu SE, Son KH, et al. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Nat Prod Res 2006, 20: 341-346.
48. Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS et al. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett 2006; 16: 2996-2999.
49. Dursina B, Reents R, Delon C, Wu YW, Kulharia M, Thutewohl M, et al. Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids. J Am Chem Soc 2006; 128: 2822-2835.